Healthcare Industry News: enGene
News Release - December 18, 2008
ConvaTec and Boehringer Technologies Announce License AgreementConvaTec Acquires Exclusive Worldwide Rights for a Negative Pressure Wound Therapy System
SKILLMAN, N.J., Dec. 18 -- (Healthcare Sales & Marketing Network) -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today it has signed a long-term global exclusive license agreement with Boehringer Technologies to market and distribute Boehringer's enGenex® Negative Pressure Wound Therapy (NPWT) System incorporating Bio-Dome(TM) Interface Technology.
Boehringer's NPWT System, launched in 2007, is an innovative technology and engineering solution that utilizes the application of negative pressure to a wound to promote healing by creating controlled tissue strain and removing excess fluid, including wound exudate. Every aspect of the System, from the wound interface to the user interface, has been designed to attain optimal clinical and economic outcomes as well as a simplified application and monitoring system for patient care.
"This agreement is further evidence of ConvaTec's commitment to expand our offerings for treating acute and chronic wounds," commented David Johnson, CEO of ConvaTec. "Negative Pressure Wound Therapy is one of the largest and fastest growing market segments in Wound Management and we are thrilled to be partnering with Boehringer to help bring advanced solutions to our customers worldwide."
"We are excited about our licensing agreement with ConvaTec, a company respected around the world for its knowledge, research and product innovations in wound care management," said John R. Boehringer, President Boehringer Laboratories. "We believe the enGenex® System will bring significant value to ConvaTec and new healing modalities to its customers. We look forward to establishing a long-term working relationship with ConvaTec."
Under the terms of the development and license agreement ConvaTec receives exclusive global marketing and distribution rights for the enGenex® NPWT System. In addition, Boehringer Wound Systems will provide ongoing manufacturing support for many components of the System, and there will be ongoing co-development between Boehringer and ConvaTec for future enhancements to this and other technologies.
ConvaTec is a leading developer and marketer of innovative medical technologies that have helped improve the lives of millions of people worldwide. With four key business divisions - Ostomy Care, Wound Therapeutics, Continence and Critical Care and Infusion Devices - ConvaTec products support health care professionals from the hospital to the community health setting. From its headquarters in Skillman, New Jersey, the company oversees more than 8,000 employees in over 90 countries serving consumers and their health care professionals on six continents. For more information, please visit www.convatec.com.
Boehringer companies are innovators in anesthesia controls, respiratory therapy instruments, suction devices, autotransfusion systems and negative pressure wound therapy (NPWT). The companies are family owned, founded by John R. Boehringer in 1972 to deliver new concepts in medical instruments and controls, and therapy systems for acute and chronic applications. Boehringer has been acknowledged as a leader in medical vacuum and suction products for over 20 years. Boehringer products are known for their leading edge engineering innovation, ultra high quality, and durability.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.